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ABSTRACT
We have recently shown that an MCF-7 tumor can be
imaged in a mouse by PET with
64Cu-labeled Peptide
nucleic acids (PNAs) tethered to the permeation pep-
tide Lys4 that recognize the uniquely overexpressed
and very abundant upstream of N-ras or N-ras related
gene (unr mRNA) expressed in these cells. Herein we
describe how the high affinity antisense PNAs to
the unr mRNA were identified and characterized.
First, antisense binding sites on the unr mRNA were
mapped by an reverse transcriptase random oligo-
nucleotide library (RT-ROL) method that we have
improved, and by a serial analysis of antisense bind-
ing sites (SAABS) method that we have developed
which is similar to another recently described
method. The relative binding affinities of oligodeoxy-
nucleotides (ODNs) complementary to the antisense
binding sites were then qualitatively ranked by a
new Dynabead-based dot blot assay. Dissociation
constants for a subset of the ODNs were determined
by a new Dynabead-based solution assay and were
found to be 300 pM for the best binders in 1 M salt.
PNAs corresponding to the ODNs with the highest
affinities were synthesized with an N-terminal
CysTyr and C-terminal Lys4 sequence. Dissociation
constants of these hybrid PNAs were determined by
theDynabead-basedsolutionassaytobeabout10pM
for the highest affinity binders.
INTRODUCTION
One general approach to targeting cancer cells with drugs and
probes make use of a cancer cell-speciﬁc or overexpressed
surface receptor that can bind to a ligand and internalize the
appended drug or probe (1–6). Another approach makes use
of antibody drug or probe conjugates to recognize a cancer
cell-speciﬁc or overexpressed surface protein (7,8). Other
approaches involve the use of enzymes overexpressed by a
cancer cell to selectively activate a prodrug or probe (9). In all
these approaches a cancer cell-speciﬁc or overexpressed pro-
tein or enzyme has to be identiﬁed and an appropriate ligand,
antibody or substrate developed to recognize it, necessitating a
great deal of research time and expense. Furthermore, patient-
speciﬁc variability and spontaneous mutations of the target
proteins during treatment could compromise the effectiveness
of a given probe or drug conjugate.
Cancer cells that have unique or overexpressed proteins,
also have unique or overexpressed mRNA precursors. Unlike
designing a ligand for a protein, designing ligands that can
recognize an overexpressed mRNA is straightforward in prin-
ciple, requiring nothing more than a Watson–Crick comple-
mentary antisense oligodeoxynucleotide (ODN) or analog.
Such antisense-based agents could be readily be made
patient-speciﬁc and could easily be adapted to deal with spon-
taneous mutations during the course of treatment. There are,
however, a number of considerations that must still be taken
into account in order to make use of an antisense strategy for
targeting probes and drugs to a cell.
TheﬁrstconsiderationisthatmessengerRNAmoleculesare
inside a cell, and before an antisense ODN or analog can
recognize and bind to the mRNA it must be able to enter
the cell. Recently, a class of peptide sequences, known as
protein transduction domains, or permeation peptides have
been identiﬁed that enable a wide variety of attached
molecules to enter cells, including ODNs and analogs
(10–12). As a result, there have been a number of reports
of attempts to image cells by way of antisense ODNs or ana-
logs attached to permeation peptides, but often the selectivity
is poor and/or the signal is weak (13–18). The limited success
of this approach to date may be due to a number of factors,
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binding afﬁnity of the antisense agent to the target sequence
due to its inaccessibility and/or conformation (19), and the use
of cleavable linkers between the antisense agent and the per-
meation peptide which would prevent the antisense agent from
exiting cells deﬁcient in the targeting mRNA.
In principle, much better cell discrimination with antisense
Peptide nucleic acids (PNAs) could be achieved by targeting
high afﬁnity binding sites on a uniquely overexpressed mRNA
that is also very abundant. In addition, the antisense agent
should be irreversibly linked to the permeation peptide to
allow it to equilibrate with the extracellular media and select-
ively concentrate in cells having high concentrations of the
mRNA. Recently, we showed that we could image an MCF-7
tumor in a mouse by PET with
64Cu-labeled PNAs bearing a
Lys4 permeation peptide, and that the best image was obtained
with an antisense PNA for the upstream of N-ras or N-ras
related gene (unr mRNA) that is highly abundant and uniquely
overexpressed in that tumor type (20). Antisense PNAs for the
unr mRNA could also be used as part of a nucleic acid trig-
gered prodrug and probe activation (NATPA) system that we
have been developing (21–25). In this paper, we describe the
general methodologies that we used to map and characterize
high afﬁnity antisense ODN and PNA binding sites on the unr
mRNA that were used in the design of the PET MCF-7
imaging agents.
MATERIALS AND METHODS
General
Image clone 5285557 containing the unr mRNA sequence
(D1S155E, NM_007158.2, GI: 20070240 and ATTC clone
#7020864) was obtained from ATTC. pZErO-1 vector used
for serial analysis of antisense binding sites (SAABS) analysis
was from Invitrogen (Carlsbad, CA). Streptavidin coated
Dynabeads were Dynabead M-280 Streptavidin from
Dynal Biotech (Brown Deer, WI). Diisopropylethylamine
(DIPEA), triﬂuoroacetic acid (TFA), m-cresol and diethyl
ether (anhydride) were purchased from Aldrich. a-N-9-
Fluorenylmethoxycarbonyl (Fmoc) protected amino acids
(Cys(Trt)-OH, Tyr(tBu)-OH and Lys(Boc)-OH) were pur-
chased from NovaBiochem. O-(7-Azabenzo-triazol-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HATU),
Fmoc-XAL PEG-PS resin, PNA building blocks (Fmoc-A-
(Bhoc)-OH, Fmoc-C-(Bhoc)-OH, Fmoc-G-(Bhoc)-OH and
Fmoc-T-OH) and other reagents and solvents for PNA and
peptide synthesis were purchased from PerSeptive Biosys-
tems. UV spectral data were acquired on a Bausch and
Lomb Spectronic 1001 spectrophotometer or Varian Cary
100 Bio UV-Visible Spectrophotometer. Matrix-assisted
laser desorption ionization (MALDI) mass spectra of PNA-
peptide conjugates were measured on a PerSeptive Voyager
RP MALDI-time of ﬂight (TOF) mass spectrometer using
sinapinic acid as a matrix and calibrated versus insulin (aver-
age [M + H
+] ¼ 5734.5) that was present as an internal stand-
ard. High-pressure liquid chromatography (HPLC) of PNAs
was carried out on Beckman Coulter System Gold 126 HPLC
system. ODN and PNA synthesis was carried out on an auto-
mated ABI 8909 synthesizer (Applied Biosystems) with a
PNA option.
Substrate preparation
Human unr mRNA. Transcription reactions were carried out
using the Promega RiboMAX Large Scale RNA production
systemutilizingtheT7promoteratthe50 endoftheunrgenein
a pBluescriptR plasmid (IMAGE clone 5285557) and linear-
izing the plasmid at the unique NdeI site at the 30 end of the
gene before transcription. Transcription was allowed to pro-
ceed with T7 RNA polymerase and NTPs for 3 h at 37 C, and
was followed by DNase I treatment, phenol:chloroform:
isoamylalcohol (25:24:1) extraction and ethanol precipitation.
NTPs were then removed with a NucAway spin column
(Ambion, Austin TX). The ﬁnal puriﬁed unr RNA was
quite homogeneous and corresponded in size to the expected
3.4 Kb transcript. For the SAABS and Dynabead-based-
assays, the unr mRNA was transcribed in the presence of
Bio-UTP.
ODNs. ODNs were either obtained from Integrated DNA
Technologies (IDT, Coralville, IA) or were synthesized by
standard solid phase phosphoramidite synthesis. Random
sequences were synthesized using a mixture of phosphoramid-
ites in a ratio of 1.5:1.25:1.15:1.0 (A:C:G:T). All ODNs were
puriﬁed by 15 or 20% denaturing polyacrylamide gels before
and after any
32P-radiolabeling. The reverse transcriptase
primer used in the reverse transcriptase random oligo-
deoxynucleotide library (RT-ROL) assay (XN9-tag) was:
d(GGATTTGCTGGTGCAGTACANNNNNNNNNX). The
primers used in the PCR ampliﬁcation step of the RT-ROL
assaywere:unr1:d(GCTGAGCTGTTGGGTATGAAG),unr2:
d(TCATCCTTTGAAACGTGTGC), unr3: d(ACGAACGT-
AATGGGGAAGTG); unr4: d(AAATCCAAGGTGACCCT-
GCT); unr5: d(TGACTGTGGGGTGAAACTGA); unr6:
d(GAGGGCGATATGAAAGGTGA); unr7: d(AACCA-
CATCCACAAAGCACA). The ODNs used in the SAABS
assay were: S1: d(GGATTTGCTGGTGCAACATG); CS1:
d(CATGTTGCACCAGCAAATCC); CS2: d(CCTCGAATT-
CAAGCTTCATG); S1-ROL-S2: d(GGATTTGCTGGTG-
CAACATGN8CATGAAGCTTGAATTCGAGG).
PNA-peptide conjugates. The hybrid PNA-peptides were syn-
thesized with a capping step in 2 mmol scale using Fmoc
chemistry and the manufacturer’s protocols, reagents and
PNA monomers. After completion of automated synthesis,
PNAs were cleaved from the solid support and the bases
were deprotected using triﬂuoroacetic acid:m-cresol (4:1)
for 2 h and then precipitated with diethyl ether. The hybrid
PNA-peptides were puriﬁed by reverse phase chromatography
on a Microsorb-MV 300-5 C-18 column, (250 · 4.6 mm col-
umn, 300 s pore size, Varian Inc.) with a 0–5% B/5 min,
5–60% B/30 min, 60–95% B/5 min, 95% B for 5 min, 95–0%/
10 min, where A ¼ 0.1% TFA in water, B ¼ 0.08% TFA in
CH3CN. The fractions containing the products were evapor-
ated to dryness in a Savant Speedvac, and redissolved in pure
water. Peptide-PNA conjugates were quantiﬁed by spectro-
photometric A260 values and characterized by MALDI-
TOF (Table 2).
Radioiodination of PNA-peptide conjugates. The PNA-
peptides were radioiodinated by a procedure described for
iodination of PNAs with
125I (13). Thus Na
131I (12 ml,
5 mCi/120 ml solution from Amersham) was added to 2 ml
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100mM NaI was added, followed by 4 ml of 1mM chloramine-
T and 4 ml of 100 mM PNA. The reaction was mixed by
micropipetting, and allowed to stand for 5 min at room tem-
perature and quenched with 4 ml of 10 mM sodium metabi-
sulﬁte. The reaction mixture was then diluted with 80 mlo f
water and placed on to a Waters Sep-Pak cartridge (Vac C18,
6cc, Part#WAT036905) thathad been prewashed with 5mlof
0.1% TFA in water. The unreacted Na131I (average of 27% of
the total radioactivity) was washed out with 10 ml of 0.1%
TFA in water. This was followed by 5–10 ml of 5% acetoni-
trile in 0.1% TFA/water, which contained little radioactivity.
The radiolabeled PNA-peptide (average of 42% of the radio-
activity) was eluted with 5 ml of 40% CH3CN in 0.1% TFA/
water, leaving an average of 31% of the total radioactivity on
the column. The average recovery of the labeled PNA-peptide
was 57%. An aliquot of the fraction containing the labeled
PNA-peptide was then diluted down to make a 100 mM stock
solution. The actual concentration was then determined based
on the activity of the solution in comparison to the 5 ml stock
solution.
Mapping assays
Modified RT-ROL mapping assay. The ODNs used for map-
ping the antisense binding sites on the unr mRNA by the
modiﬁed RT-ROL assay are shown in Figure 2. The mapping
was carried out by heating the RNA at 65 C for 5 min with
dNTPs followed by a quickly chilling on ice for 1min and then
adding the random ODN library primer XN9-tag, RNasIn
(Promega, Madison WI) RNase inhibitor and SuperScript II
reverse transcriptase (Invitrogen Life Technologies) for
another 5 min. The reaction was incubated at 42 C
for 50 min, and the enzyme inactivated by heating at 70 C
for 15 min. Then 50-endlabeled PCR primer, dNTPs and Taq
polymerase were added and subjected to an initial incubation
at 94 C for 3 min, followed by 30 cycles of PCR (1 min 94 C,
1 min 55 C and 1 min 72 C). The products were then separ-
ated on 6% denaturing polyacrylamide gels.
SAABS assay. Streptavidin coated Dynabeads were ﬁrst
washed with solution A (DEPC-treated 0.1 M NaOH and
DEPC-treated 0.05 M NaCl), followed by three washes
with solution B (DEPC-treated 0.1 M NaCl), and then washed
two times with 100 ml of hybridization solution [1M NaCl and
Tris–HCl (pH 7.4)]. The beads were then resuspended in 50 ml
of hybridization solution. The biotinylated RNA (3 mlo f
3 mg/ml) was incubated with 45 ml of hybridization solution
at 65 C for 5 min, and then cooled at room temperature for
10 min. The ODN containing the random 8mer (S1-ROL-S2)
was then annealed with the complementary ODNs CS1 and
CS2 in hybridization buffer (50 ml) by heating at 65 C for
5 min, and then cooled to room temperature for 10 min. The
RNA solution was then mixed with S1-ROL-S2 CS1 CS2
together with 2 ml RNasIN, and incubated at 27 C for 1 h.
The solution of beads was then added and resuspended every
5 min by pipetting for a total of 15 min. Following the incuba-
tion, the beads were separated with a magnet and washed
6 times with the hybridization solution and then resuspended
in 100 mlo fH 2O. Thirty cycles of PCR were then carried out
on the beads with Taq DNA polymerase, and S1 and CS2
primers. After ampliﬁcation, the reaction mix was directly
loaded on to a 12% denaturing PAGE gel and electrophoresed
to separate the 48 bp PCR product. The 48 bp PCR band was
excised and the eluted product digested with NlaIII at 37 C
overnight to release the 12mer product from the tags which
was puriﬁed by 20% denaturing PAGE gel. The 12mer pro-
ducts were ligated with T4 DNA ligase and ATP at 16 C for
2 h. Concatemers were isolated usingthe Qiaquick Gel Extrac-
tion Kit (Qiagen, Valencia, CA), following the manufacturer’s
manual. The mixture was then electrophoresed on a 1% agar-
ose gel (TAE) and fractions with 300–500 bp length were
excised. Concatemers were ligated into the SphI site of
pZErO-1 (Invitrogen) with T4 DNA ligase and ATP for 4 h
at 16 C and then transfected into Escherichia coli, following
the manufacturer’s manual (Oneshot  Top10, Invitrogen).
The transfectants were plated on low salt Luria–Bertani
(LB) plates containing 50 mg/ml Zeocin  (Invivogen, San
Diego, CA) and incubated for about 18 h at 37 C. Zeocin 
resistant transformants were picked using pipette tips, incub-
ated in 5 ml SOB containing 50 ml/ml Zeocin  and grown
overnight at 37 C. Plasmid DNA was prepared by the Plasmid
mini prep kit (Qiagen). Plasmids containing sizable inserts
were then forwarded for sequence analysis. The sequences
were analyzed by a computer program written expressly for
this purpose. The program ﬁrst extracts the 8mer sequences
from between Nla III sites, and then scans for a perfect match
between either the sense or antisense 8mer sequences and
the mRNA sequence. If either the sense or antisense 8mer
sequence matches uniquely, each matching base in the
mRNA is assigned one point. If the sequence matches n dif-
ferent sites, each matching base at each site is assigned 1/n
points. This sequence of steps is repeated for sequences only
matching 6–7 bases.
Binding assays
Dynabead-based dot blot assay. Strepavidin-coated Dyna-
beads were washed following the manufacturer’s protocol,
and then washed two times with hybridization buffer [1 M
NaCl,0.5mMEDTAand20mMsodiumcacodylate(pH7.0)].
After the last wash, the beads were resuspended in hybridiza-
tion buffer in the presence of biotinylated unr mRNA, incub-
ated for 30 min at 37 C, and mixed occasionally by ﬂicking
the tube with a ﬁnger. The tube containing the beads was then
placed on a magnetic stand for 1 min, following which the
supernatant was removed and discarded. The beads were then
washed three times with hybridization buffer and
then resuspended in hybridization buffer in the presence of
1 pmol of
32P-labeled ODN, incubated for 30 min at 37 C
with periodic agitation by ﬂicking. After washing three times
as described above, the beads were resuspended in 20 ml
hybridization buffer, and 2 ml was spotted on a Nylon
membrane.
Dynabead-based ODN binding assay. The radiolabeled ODN
(100 pM) was incubated with the 0.003–10 nM of biotinylated
mRNA and 1 ml of RNasIN inhibitor for 4 h at 37 Ci na
total volume of 100 ml. Then streptavidin coated Dynabeads
were added and mixed for 30 min. The beads were then
separated by a magnet and the solution removed. The beads
were resuspended in 100 ml of water and both solutions coun-
ted by liquid scintillation to give free and bound fractions
directly.
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carried out as described above for the ODNs in Bio-Rad EZ
Micro test tubes in triplicate. Speciﬁcally, the radiolabeled
PNA (13–26 pM) was incubated with 0.1–1000 pM of bio-
tinylated mRNA and 1 ml of RNasIN inhibitor for 4 h at 37 C
in a total volume of 100 ml of 0.1 M NaCl, 50 mM EDTA and
2 mM cacodylic acid. Then 5 ml of streptavidin coated Dyna-
beads were added and mixed for 2 h. The beads were separated
by a magnet and the supernatant transferred to a liquid scin-
tillation vial. The beads were washed with 100 ml buffer three
times and the washes transferred to the ﬁrst scintillation vial.
The beads were then transferred to a liquid scintillation vial by
suspending three times in 100 ml of buffer. Liquid scintillation
ﬂuid (5 ml of CytoScint plus) was then added and both scin-
tillation vials counted by liquid scintillation to give free and
bound fractions directly.
Binding data analysis. The dissociation constants were
determined by non-linear least squares ﬁtting of the fraction
bound versus RNA concentration data to the analytical expres-
sion shownbelow for a two state binding equilibrium usingthe
Kalaidagraph program.
FB¼NSB
þ
SB*ðð½L þKdþ½RNA Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½L þKdþ½RNA Þ
2 4 ½L  ½RNA 
q
Þ
2 ½L 
FB is the experimentally determined fraction of bound ODN or
PNA ligand L, NSB¼fraction of ligand L that is non-
speciﬁcally bound (ﬁtted parameter), SB is the fraction of
ligand that can be speciﬁcally bound and was set equal to
(1 NSB) when the ligand was an ODN, [L]¼total ligand
concentration, Kd¼dissociation constant of the ligand (ﬁtted
parameter) and [RNA]¼total RNA concentration. A lower
limit of the binding constant could only be estimated for
incomplete binding curves. For the PNA binding analysis,
three sets of data were averaged and weighted according to
their standard deviations and SB was also ﬁtted to correct for
the presence radioactive material that appeared to show no
binding afﬁnity for the RNA (the curves plateaued at values
below 100%).
RESULTS AND DISCUSSION
Selection of a cancer-specific overexpressed mRNA
To validate our antisense cell targeting approach, we searched
the NCBI serial analysis of gene expression (SAGE) database
(http://www.ncbi.nlm.nih.gov/SAGE/) for abundant mRNAs
that are >10-fold overexpressed in standard cancer cell lines
compared to any normal cell lines. In doing so we discovered
that the well studied MCF-7 breast cancer cell line contains an
almost 10-fold higher amount of the unr (upstream of N-RAS)
mRNA (GI: 41282241) (26,27), than normal cell lines, and is
present at a level of about 5000–6000 tags/million, or roughly
the same number of copies per cell. We found a full length
cDNA clone from the I.M.A.G.E. consortium (5285557 from
the NIH_MGC_96 library, UniGene Library 6001), and
obtained the pBluescriptR vector containing the cDNA
through the American Tissue Culture Collection (ATCC),
#7020864). We were able to produce the 3.4 kB unr
mRNA in high yield and homogeneity by in vitro transcription
with T7 RNA polymerase.
Modified RT-ROL assay for identifying antisense
binding sites
Because mRNA is folded in vivo, much of its sequence is
inaccessible to an antisense ODN either because of
intramolecular base pairing to a complementary RNA
sequence within the mRNA, or because it is buried within
the three dimensional structure and physically inaccessible
(28). It is also likely that many otherwise accessible sites
are also blocked by binding to proteins in vivo. A number
of chemical, physical and enzymatic techniques have been
developed to map the accessible sites on short folded
mRNAs, but most are unsuitable for mapping sites on long
mRNA sequences, either due to electrophoretic resolution
problems or the expense associated with making the required
custom DNA arrays (29). To identify the sites on the unr
mRNA that could potentially bind PNAs in vivo, we adopted
and improved upon a recently reported length-independent
RT-ROL method. This method uses a random oligonucleotide
library attached to a PCR tag to prime RT followed by PCR
ampliﬁcation with primers corresponding to the PCR tag and
different sections of the target mRNA (30).
In the original method, the priming end was a completely
random sequence, making it difﬁcult to assign the PCR pro-
ducts to a speciﬁc-site on the mRNA because of the difﬁculty
in determining the precise length of the PCR product. To
improve the precision of the method we synthesized a set
of four separate random 9mer primers terminating in either
A, C,GorT(Figure1) thereby making it much easierto assign
the PCR product bands to speciﬁc sequences by the pattern of
bands produced. The entire unr mRNA was mapped in this
way using 7 forward primers (unrX) for each section of the
transcript and the PCR tag on the random ODN library
(Figure 2A). The pattern of PCR bands formed (Figure 2B)
were analyzed in comparison to the mRNA sequence to reveal
the ODN binding sites (Figure 3). Approximately 50 antisense
sites on the unr mRNA were identiﬁed by this RT-ROL assay.
Figure 1. Modified RT-ROL assay. In this assay antisense binding sites are
identified by the ability of a random 9mer oligodeoxynucleotide library (ROL)
terminating a specific base and a PCR tag to prime complementary DNA
(cDNA) synthesis by reverse transcriptase (RT). The cDNA is then amplified
by PCR with a radiolabeled primer having the same sense as the RNA, and an
unlabelled primer having the same sequence as the PCR tag.
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A potential problem with the RT-ROL assay is that the
priming of RT might be sensitive to secondary and tertiary
structure, and as a result, the intensity of the PCR bands pro-
duced in the RT-ROL assay might not correspond directly to
the actual binding afﬁnity of the ODN. To circumvent this
problem we developed an enzyme independent method for
mapping antisense binding sites that adapts methodology
used in SAGE to determine which members of a random
library of ODNs bind to an mRNA molecule and with what
frequency. The method, which we call SAABS for serial ana-
lysis of antisense binding sites is shown in Figure 4A. In the
ﬁrst step, members of a random oligonucleotide library that
bind to the mRNA are separated from those that do not. In the
second step, the selected sequences are PCR ampliﬁed, restric-
ted, concatenated by ligation and then cloned. In the third step,
the clones are sequenced and the sequences retrieved from
between the restriction sites and then aligned with the RNA
sequence by a computer program.
Recently, another group has reported a similar strategy for
identifying antisense binding sites, which they called MAST
for mRNA accessible site tagging (31). Our method is very
similar to theirs, which also uses streptavidin coated Dyna-
beads, except that we use an 8mer random nucleotide library
instead of an 18mer library, add the Dynabeads after binding
of the ODNs to the biotinylated mRNA, and concatenate the
antisense sequence tags before sequencing, which they do not.
In our procedure (Figure 4A) a random 8mer ODN library
linked to two PCR tags is incubated with a biotinylated mRNA
molecule that is bound to a strepavidin-coated Dynabead. The
PCR tags are prevented from hybridizing to the mRNA by
binding to the complementary ODNs CS1 and CS2. Following
incubation with the mRNA, the Dynabeads are separated by
a magnet and washed to remove unbound ODNs. The bound
ODNs are then PCR ampliﬁed with primers S1 and CS2,
restricted with NlaIII to give 12mers that are isolated by dena-
turing 20% PAGE, concatenated by ligation, cloned into the
pZErO-1 vector and transfected into E.coli. Plasmids contain-
ing inserts are then sequenced, and the 8mer sequence between
the NlaIII restriction sites were extracted by a computer pro-
gram and both strands matched to complementary sites on the
RNA sequence.
The program scored each matching nucleotide in the mRNA
by the number of times that it was matched to an 8mer
sequence divided by the number of other sites that also
matched that same antisense sequence. If a complete match
was not found, the process was repeated for all possible 7mer
and then 6mer sequences. The relative frequency of the
sequences retrieved by the SAABS method are plotted against
their position as shown in Figure 4B. Some of these sites were
not detected by the RT-ROL assay and are labeled with a
S. Presumably, these sites correspond to binding sites that
reverse transcriptase may not have been able to extend. Fifteen
of the highest frequency sites uniquely determined by this
method were chosen for further analysis.
Affinity screening of potential antisense ODNs by a
Dynabead-based dot blot assay
To determine the relative afﬁnity of ODNs for the antisense
binding sites determined by the RT-ROL and SAABS method
Figure 2. (A) Primers used to map ODN accessible sites on unr transcript.
Sequences of unrX is given in the experimental section. (B) Phosphorimage of
polyacrylamidegels ofthePCRproductsforeachsection(X ¼ 1–7)oftheunr
transcript. Boxed site is analyzed in Figure 3.
Figure3. InterpretationoftheRT-ROLgel.(A)Blowupofboxedsectionofgel
in Figure 2 showing the approximate alignment of the bands with standard
lengthmarkers.(B)AlignmentoftheobservedbandswiththemRNAsequence,
taking into account the sequence of the mRNA and the terminal nucleotide on
the primer, along with the fact that the PCR tag adds an additional 20 nt to the
extra 9 random nucleotides in the PCR amplified product band.
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In our ﬁrst attempts, we tried to use a standard dot blotting
method that involves photocrosslinking of antisense ODNs to
a nylon membrane and then quantifying the amount of
radiolabeled mRNA that becomes bound. Unfortunately,
this technique was not very reproducible, probably because
of the non-uniformity of UV crosslinking of ODNs of varying
sequence to the nylon membrane.
In developing a better dot blotting method for screening
ODN binding sites, we investigated the use of Dynabeads
to anchor biotinylated unr mRNA to the blot. We found
that the binding capacity of the streptavidin coated beads
for biotinylated unr mRNA produced by transcription in the
presence of Bio-dUTP, to be about 1 pmol of RNA/20 mlo f
Dynabeads (Figure 5A) and that the Dynabead bound mRNA
could bind about one half an equivalent of a radiolabeled
antisense ODN under saturating conditions (Figure 5B).
The Dynabead-based dot blot assay was then used to qual-
itatively assess the relative binding afﬁnities of 20mer ODNs
for the accessible antisense sites identiﬁed by the RT-ROL and
SAABS method (Figure 5C and D). High and low afﬁnity
ODNs were selected for the quantitative binding assays to
provide a range of afﬁnities for comparison of the ODN and
PNA binding afﬁnities. The sequences were further optimized
by shifting the sequence to the 50 or 30 end to minimize self-
complementarity and shortening to 15mers to minimize unfa-
vorable electrostatic interactions. These second generation
ODNs are labeled X-2, where X ¼ the parental ODN. On
the basis of this assay, about 15 ODNs were selected for
quantitative assays. We also selected an additional four anti-
sense ODNs corresponding to sites that were not detected by
either the RT-ROL or SAABS assay, and a sense sequence
(PNA 50S), and two unrelated sequences L-15 and V-12.
Quantitative Dynabead-based assay of
antisense ODN binding affinity
Initially we attempted to obtain ODN binding constants for the
unr mRNA by a Centricon centrifugal ﬁltration assay (32). In
this assay 50 32P-radiolabeled ODN is incubated with increas-
ing concentrations of mRNA, and bound ODN is separated
from free ODN by centrifugation through a ﬁlter that does not
allow the mRNA or any ODN-bound mRNA to pass through
the ﬁlter. Unfortunately, this method did not work very well in
our hands due to problems with non-speciﬁc binding to the
ﬁlter.
To get around the non-speciﬁc binding problem, we
developed an assay method which makes use of a magnetic
Figure 4. SAABS assay. (A) SAABS procedure. A random 8mer oligodeoxynucleotide library (ROL) flanked by two PCR tags is first incubated with biotinylated
mRNA.ThemRNAboundODNisthenseparatedfromfreeODNbybindingthebiotinylatedmRNAtoastreptavidincoatedDynabead,whichisthenseparatedfrom
the unbound sequence by a magnetic field. The bound sequence is then PCR amplified with S1 and CS2, restricted with NlaIII, concatenated by ligation, cloned in
pZErO-1 and sequenced. (B) Frequency distribution of the antisense binding sites on the unr mRNA obtained from the SAABS assay. The 8mer sequences were
retrievedfrom the sequencedclonesandaligned withthemRNAsequence.Someof thesitesidentifiedcorrespondto sitesfoundbythe RT-ROLassay(13and 46),
whereas others were uniquely detected by the SAABS assay and denoted with an S prefix (S1, S3, S5 and S7).
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free ODNs in solution without the use of a ﬁlter. Following
equilibration of the ODN with biotinylated unr mRNA, the
mRNA and any bound ODN was bound to streptavidin coated
Dynabeads and then separated from free ODN using a mag-
netic ﬁeld. The Dynabead method gave much better results
than the Centricon-basedmethod, thoughit appearedthatthere
was a variable amount of non-speciﬁc binding which resulted
in measurable radioactivity in the Dynabead fraction at low
concentrations of mRNA where no ODN should have been
bound (Figure 6). This non-speciﬁc binding could be easily
subtracted during the non-linear least squares ﬁtting procedure
used to determine the dissociation constants (see experimental
section).
As can be seen in Table 1, ﬁve ODNs had Kdso f1n Mo r
less (entries 1–5), and 9 had Kdso f<3 nM (entries 1–9). When
the relative binding afﬁnities for the ODNs are compared to
the relative intensities of the spots in the dot blot assay there
appears to be a reasonable correlation with a few exceptions.
All those with dissociation constants >10 nM (entries 10–15)
appeared weak on the dot blot assay with the exception of
35-2 which appeared strong. Likewise all the ODNs with
dissociation constants of <3 nM appeared strong with the
exception of S3-2 and 9 which appeared weak. For the
most part then, the dot blot method appears to be a reasonable
way of rapidly screening for high afﬁnity binders, which can
then be veriﬁed by the quantitative assay. Antisense ODNs
corresponding to sites not detected by either the RT-ROL or
SAABS assay showed little if any afﬁnity (Figure 6E, Table 1,
entries 16–19).
Design and synthesis of the antisense PNAs
Because ODNs are readily degraded in vivo and can addition-
ally lead to cleavage of the mRNA transcript to which they are
bound via the combined action of RNAse H, they are not
suitable for in vivo targeting purposes. PNAs are, however,
ideally suited for this purpose because they are nucleic acid
analogs in which the enzymatically labile phosphodiester
backbone has been replaced by an unnatural peptide backbone
Figure 5. Dynabead-baseddotblotassayto determinerelativebindingaffinityofODNs.(A)DeterminingtheloadingcapacityofthestreptavidincoatedDynabead
by titrating 20 ml of bead solution in 40 ml total volume of 0.5 M NaCl with biotinylated radiolabeled unr mRNA. (B) Determining the ml of Dynabead bound RNA
neededtocompletelybind1pmolofODN5inatotalvolumeof40ml.(CandD)SolutionsofRNAwereincubatedwith1pmolofODN[1–54fromRT-ROLassayand
57–68 (S1-S12) from the SAABS assay] and then incubated with 10 ml of Dynabeads and spotted on Nylon membrane. (C) is a photograph of blot showing equal
loadingofbeads.(D)is a radiogram showingrelativeamountsofretainedODN.ODNscorrespondingto circledspotswerefurtherstudiedbyquantitativemethods.
6706 Nucleic Acids Research, 2005, Vol. 33, No. 21Figure6.CurvefitsofthedatafromtheDynabeadODNbindingassay.(A–C)antisenseODNsforsitesidentifiedbytheRT-ROLassay,(D)antisenseODNsforsites
identified by the SAABS assay, and two unrelated ODNs, L-15 and V-12, (E) antisense ODNs for sites not identified by either the RT-ROL or SAABS assay.
Nucleic Acids Research, 2005, Vol. 33, No. 21 6707(33,34). As a result, PNAs are highly resistant to enzymatic
degradation (35), do not activate RNAse H activity (36), have
a high afﬁnity for complementary mRNA and can invade
duplex regions (37).
Therefore, we designed hybrid PNAs corresponding to the
four ODNs that showed the highest binding afﬁnity, and ODN
5-2 which showed slightly less afﬁnity. We also synthesized
PNAscorresponding tofourODNsshowing lowafﬁnityandto
the four ODNs corresponding to sites not detected by either
method. The sense sequence, PNA50-2S, corresponding to the
PNA50-2 binding site was also made as a control. The PNAs
were synthesized with a recently reported four lysine permea-
tion peptide (38,39) at the C-terminus, which was used for
our PET imaging studies in mice (20), and to increase water
solubility and mRNA binding afﬁnity. A cysteine-tyrosine
sequence was added to the N-terminal end to enable sub-
sequent attachment of reporter groups to the cysteine and
radioiodination of the tyrosine. The PNAs were synthesized
by standard solid phase Fmoc chemistry on an ABI Expedite
8909 automated synthesizer, puriﬁed by reverse phase HPLC,
and characterized by molecular weight determination by
MALDI-TOF (Table 2).
Quantitative Dynabead-based assay
of antisense PNA binding affinity
The binding afﬁnity of the PNAs for the unr mRNA were
determined by monitoring bound and free
131I-labeled PNA
as a function of mRNA concentration using the Dynabead
assay method that we developed to quantify ODN binding
to the mRNA (Figure 7). We chose 131I to label the PNAs
because of thehigh speciﬁc activityinwhich it canbeobtained
and its short half-life of 8 days. The PNAs were radiolabeled
by a procedure previously used to label PNAs with
125I and
Chloramine-T (13).
We also checked the integrity of the PNA produced under
these conditions by repeating the labeling experiment with a
short PNA test sequence, DOTA-Tyr-ATGC-Lys (20), with
non-radioactive iodine by the chloramine-T method and also
by IODO-beads and analyzed the products by MALDI. We
found that at a 5 min reaction time, both methods lead prim-
arily to the mono-iodinated compound and some of the
diiodinated compound (tyrosine can react twice), but that at
longer times, other products are produced (data not shown).
Thus the 5 min time period was used for radiolabeling the
Cys-Try-PNA-Lys4 by
131I.
In the ﬁrst set of PNA binding experiments we discovered
that we were not recovering all the radioactivity and were able
to trace the loss to non-speciﬁc binding of the PNA to the
microfuge tubes that we were using for the incubations. After
ordering and testing a number of tubes and microtiter plates
advertised as minimizing binding of peptides and nucleic
acids, we found that Corning NBS microtiter plates and the
more convenient Bio-Rad EZ Micro 1.5 ml test tubes had the
lowest non-speciﬁc binding afﬁnity for the PNAs.
Table 1. Binding affinity of the antisense ODNs by the Dynabead assay
Entry Site Code ODN sequence Kd (nM)
1 2851 50-2 TGGTGTGCTTTGTGG 0.3 ± 0.1
2 676 7-2 TTTCCCAGTCCGTCG 0.3 ± 0.1
3 1414 S5-2 TTTGTCACGTCGGTC 0.7 ± 0.2
4 901 S3-2 ATCTCCAGTTTCCAG 0.8 ± 0.2
5 1145 16-2 CATTTCTGTCCTTGA 1.0 ± 0.3
6 1802 26-2 CATCCTCAGCCTCCT 1.1 ± 0.3
7 727 9 ATTCGTTCTTCAGGGAGGAT 1.2 ± 0.6
8 839 13-2 CACTTCCCCATTACG 1.4 ± 0.6
9 476 5-2 TATGTCCATTGTTGT 1.5 ± 0.7
10 2020 32 CCAAAATTATCCTTCAGAGT >10
11 1396 21 TCTGTTGAAATATTAAACCT >10
12 1927 29-2 CCTCTGTTTGTCACT >10
13 2114 35-2 TGTCCCCCAGTTCCA >10
14 1389 20 AATATTAAACCTAACATGGT >10
15 2115 S7 ATGTCCCCCAGTTCC >100
16 1012 1012 TCCTTCATGGCACAAACTAC >100
17 1263 1263 GGTTTTTACTGGGTACTTTT >100
18 1526 1526 CACACACTTGATGAAACCAA >100
19 1653 1653 TAATAGCATGATTTCTTTGA >100
20 na V-12 CGATTGGAGCGC >100
21 na L-15 AGATCGCAACTCATA >100
TheantisensesitereferstothepositioninthemRNA(startcodonat448)thatis
complementarytothe30 endofthecorrespondingODN.ThecodenumberX-Y
referstoODNXusedinthedotblotexperiments,andiffollowedbya2refersto
an optimized second generation sequence that overlaps the original sequence.
The S prefix refers to a site uniquely identified by the SAABS assay.
Table 2. Binding affinity of Cys-Tyr-PNA-Lys4 by the Dynabead-based solution binding assay
Entry Site Code Calcd M + 1
a Obsvd M + 1
a PNA sequence Kd (pM)
1 899 S3-2 5571 5576 TATCTCCAGTTTCCAGCT 6 ± 3
2 673 7-2 5588 5594 TTTCCCAGTCCGTCGGTC 12 ± 4
3 476 5-2 5641 5646 CATTATGTCCATTGTTGT 17 ± 6
4 2848 50-2 5779 5784 TGGTGTGCTTTGTGGATG 20 ± 7
5 1414 S5-2 5651 5659 TAATTTGTCACGTCGGTC 49 ± 6
6 1927 29 5592 5594 CCTCTGTTTGTCACTAAT 300 ± 30
7 2020 32 5603 5604 CCAAAATTATCCTTCAGA 380 ± 60
8 2114 35 5587 5591 TGTCCCCCAGTTCCAGGC 680 ± 100
9 1389 20 5658 5660 TATTAAACCTAACATGGT 820 ± 190
10 1263 1263 5653 5655 TTTTTACTGGGTACTTTT 340 ± 60
11 1012 1012 5604 5608 CTTCATGGCACAAACTAC 650 ± 170
12 1526 1526 5637 5640 CACACTTGATGAAACCAA 1000 ± 310
13 1653 1653 5680 5683 ATAGCATGATTTCTTTGA 1000 ± 190
14 na
b 50-2S 5562 5568 CATCCACAAAGCACACCA >10 000
ThesitereferstothepositioninthemRNAthatiscomplementarytothe30 endofthePNAsequenceshown(thestartcodonisat448).ThecodenumberX-Yisthesame
as that for the corresponding ODN listed in Table 1.
aCalculated MW is for the average M + 1 ion, observed MW is for the M + 1 ion detected by MALDI-TOF.
bnot applicable.
6708 Nucleic Acids Research, 2005, Vol. 33, No. 21Figure 7. Curve fitsto the PNAbindingdatafrom the Dynabeadassay.(A–C) antisensePNAs correspondingto highaffinity antisenseODNsidentifiedby theRT-
ROL assay, (D) sense PNA corresponding to PNA50-2, (E and F) antisense PNAs corresponding to high affinity antisense ODNs identified by the SAABS assay,
(G)antisensePNAscorrespondingtolowaffinityantisenseODNsidentifiedbytheRT-ROLassay,(H)antisensePNAscorrespondingtositesnotidentifiedbyeither
assay. The error bars represent the standard deviation of the average of three experiments and are not shown for (G) and (H) for clarity.
Nucleic Acids Research, 2005, Vol. 33, No. 21 6709Triplicate sets of data were obtained and a plot of % bound
as a function of RNA concentration was ﬁt to a simple two
state binding equilibrium as we had done for the ODNs
(Figure 7). The Kds for the PNAs are tabulated in Table 2.
As expected, the PNAs corresponding to the high afﬁnity
ODNs show very high binding afﬁnity (low Kds) for the
unr mRNA with Kds that range from 7 to 50 pM at 0.1 M
salt (entries 1–5). The PNAs corresponding to the low afﬁnity
ODNs, showed higher Kds of 300–820 pM (entries 6–9). Sur-
prisingly, the PNAs corresponding to sites not detected by
either the RT-ROL or SAABS assays also bound with similar
Kds of 340–1000 pM (entries 10–13) found for the low afﬁnity
sites. The sense PNA 50-2S, appeared to have essentially no
afﬁnity for the RNA (entry 14).
The binding afﬁnities of the PNAs for the unr mRNA are
much greater (lower Kds) than those of the corresponding
ODNs. The difference in binding afﬁnity between the PNAs
andODNsislikelytobemuchgreaterinvivobecause thePNA
dissociation constants were obtained at the physiological con-
centration of 0.1 M NaCl, whereas the ODN dissociation con-
stants were acquired at 1 M salt. At 0.1 M salt the Kds for the
ODNs are expected to be greater due to electrostatic repul-
sions, whereas the PNAs are expected to have lower Kds due to
favorable electrostatic attraction with the Lys4 tail. PNA
50-2S, which is identical in sequence to the mRNA target,
showed no signiﬁcant binding in the range of RNA concen-
trations that bound tightly to the antisense sequences.
The signiﬁcant binding afﬁnity of the PNAs to sites not
detected by either the RT-ROL or SAABS assay (Kdso f
340–1000 pM) might be attributable to the ability of PNA
to invade and bind to regions of folded RNA that might not
bind ODNs because of electrostatic repulsion. Even though,
the best of these PNAs (PNA 1927) has >50-fold less afﬁnity
than the highest afﬁnity PNA identiﬁed by the SAABS assay
(PNA S3-2), and >25-fold less than the highest afﬁnity PNA
found by the RT-ROL assay (PNA 7-2). Likewise, PNAs
corresponding to low afﬁnity antisense ODNs bind with
less afﬁnity (300–820 pM) than those PNAs corresponding
to the high afﬁnity antisense ODNs. These results suggest
that accessibility of a site to an ODN may be a prerequisite
for high afﬁnity PNA binding. Thus it would appear that the
RT-ROL and SAABS assay offer a more direct and efﬁcient
way to ﬁnd high afﬁnity antisense PNAs than might be found
by simply screening PNAs to randomly selected sites.
CONCLUSION
We have identiﬁed high afﬁnity antisense binding sites on unr
mRNA produced in vitro through an improved RT-ROL and
SAABS mapping methods, and have quantiﬁed their binding
afﬁnity by a new Dynabead-based solution assay. The two
mapping methods identiﬁed many of the same antisense bind-
ing sites, but there were also a few high afﬁnity sites identiﬁed
by the SAABS method that were not detected by the RT-ROL
method, presumably because reverse transcriptase was unable
to bind or extend an ODN at that site. The afﬁnity of PNAs for
these sites on the unr mRNA in vivo remains to be determined,
although our recent results with PET imaging MCF-7 tumors
in mice with derivatives of PNA50-2, PNA5-2 and PNA7-2
and PNA50-2S are consistent with a contribution from an
antisense mechanism. The methods that we improved upon
and developed for mapping and quantifying the antisense
binding sites might also be useful for designing siRNA agents,
and for guiding RNA folding calculations.
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